Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus BRII-198(Lomisivir): a retrospective cohort study

{ 'indexed': {'date-parts': [[2024, 4, 20]], 'date-time': '2024-04-20T00:28:59Z', 'timestamp': 1713572939229}, 'reference-count': 22, 'publisher': 'Springer Science and Business Media LLC', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2024, 4, 19]], 'date-time': '2024-04-19T00:00:00Z', 'timestamp': 1713484800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}, { 'start': { 'date-parts': [[2024, 4, 19]], 'date-time': '2024-04-19T00:00:00Z', 'timestamp': 1713484800000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}], 'funder': [ { 'name': 'Chongqing Special Research Project for Novel Coronavirus Pneumonia Prevention and ' 'Control', 'award': ['No.csct2020jscx-fyzxX0012']}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'abstract': '<jats:title>Abstract</jats:title><jats:sec>\n' ' <jats:title>Background</jats:title>\n' ' <jats:p>Monoclonal antibody therapy for Covid-19 springs up all over the ' 'world and get some efficiency. This research aims to explore the treating effect of ' 'BRII-196(Ambavirumab) plus BRII-198(Lomisivir) on Covid-19.</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Methods</jats:title>\n' ' <jats:p>In this retrospective cohort research, patients received standard ' 'care or plus BRII-196 /BRII-198 monoclonal antibodies. General comparison of clinical indexes ' 'and prognosis between Antibody Group and Control Group was made. Further, according to the ' 'antibody using time and patients’ condition, subgroups included Early antibody group, Late ' 'antibody group, Mild Antibody Group, Mild Control Group, Severe Antibody Group and Severe ' 'Control Group.</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Results</jats:title>\n' ' <jats:p>Length of stay(LOS) and interval of Covid-19 nucleic acid from ' 'positive to negative of Antibody Group were 12.0(IQR 9.0–15.0) and 14.0(IQR 10.0–16.0) days, ' 'less than those(13.0 (IQR 11.0–18.0) and 15.0 (IQR 12.8–17.0) days) of Control ' 'Group(<jats:italic>p</jats:italic>\u2009=\u20090.004, <jats:italic>p</jats:italic>\u2009' '=\u20090.004). LOS(median 10days) of Early Antibody Group was the shortest, significantly ' 'shorter than that of Control Group (median 13days)(<jats:italic>p</jats:italic>\u2009' '&lt;\u20090.001). Interval(median 12days) of Covid-19 nucleic acid from positive to negative ' 'of Early Antibody Group also was significantly shorter than that of Control Group(median ' '15days) and Late Antibody Group(median 14days)(<jats:italic>p</jats:italic>\u2009=\u2009' '0.001, <jats:italic>p</jats:italic>\u2009=\u20090.042). LOS(median 12days) and ' 'interval(median 13days) of Covid-19 nucleic acid from positive to negative of Mild Antibody ' 'Group was shorter than that of Mild Control Group(median 13days; median ' '14.5days)(<jats:italic>p</jats:italic>\u2009=\u20090.018, <jats:italic>p</jats:italic>\u2009' '=\u20090.033).</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Conclusion</jats:title>\n' ' <jats:p>The neutralizing antibody therapy, BRII-196 plus BRII-198 could ' 'shorten LOS and interval of Covid-19 nucleic acid from positive to negative. However, it ' 'didn’t show efficacy for improving clinical outcomes among severe or critical ' 'cases.</jats:p>\n' ' </jats:sec>', 'DOI': '10.1186/s40360-024-00753-7', 'type': 'journal-article', 'created': {'date-parts': [[2024, 4, 19]], 'date-time': '2024-04-19T10:01:45Z', 'timestamp': 1713520905000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Treatment for Covid-19 with SARS-CoV-2 neutralizing antibody BRII-196(Ambavirumab) plus ' 'BRII-198(Lomisivir): a retrospective cohort study', 'prefix': '10.1186', 'volume': '25', 'author': [ {'given': 'Qin', 'family': 'Yalan', 'sequence': 'first', 'affiliation': []}, {'given': 'Hao', 'family': 'Lingfang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Liu', 'family': 'Xisong', 'sequence': 'additional', 'affiliation': []}, {'given': 'Liang', 'family': 'Run', 'sequence': 'additional', 'affiliation': []}, {'given': 'Zhang', 'family': 'Junjing', 'sequence': 'additional', 'affiliation': []}, {'given': 'Zhang’', 'family': 'An', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2024, 4, 19]]}, 'reference': [ { 'key': '753_CR1', 'doi-asserted-by': 'publisher', 'first-page': '582', 'DOI': '10.1016/j.arcmed.2020.04.021', 'volume': '51', 'author': 'S Hanaei', 'year': '2020', 'unstructured': 'Hanaei S, Rezaei N. COVID-19: developing from an outbreak to a pandemic. ' 'Arch Med Res. 2020;51:582–4.', 'journal-title': 'Arch Med Res'}, { 'issue': '10223', 'key': '753_CR2', 'doi-asserted-by': 'publisher', 'first-page': '497', 'DOI': '10.1016/S0140-6736(20)30183-5', 'volume': '395', 'author': 'C Huang', 'year': '2020', 'unstructured': 'Huang C, et al. Clinical features of patients infected with 2019 novel ' 'coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.', 'journal-title': 'Lancet'}, { 'issue': '5', 'key': '753_CR3', 'doi-asserted-by': 'publisher', 'first-page': '1825', 'DOI': '10.1002/jmv.27588', 'volume': '94', 'author': 'Y Araf', 'year': '2022', 'unstructured': 'Araf Y, Akter F, Tang YD, et al. Omicron variant of SARS-CoV-2: ' 'genomics, transmissibility, and responses to current COVID-19 vaccines. ' 'J Med Virol. 2022;94(5):1825–32.', 'journal-title': 'J Med Virol'}, { 'issue': '1', 'key': '753_CR4', 'doi-asserted-by': 'publisher', 'first-page': 'e2250647', 'DOI': '10.1001/jamanetworkopen.2022.50647', 'volume': '6', 'author': 'JW Senefeld', 'year': '2023', 'unstructured': 'Senefeld JW, Franchini M, Mengoli C, et al. COVID-19 convalescent plasma ' 'for the treatment of immunocompromised patients: a systematic review and ' 'meta-analysis. JAMA Netw Open. 2023;6(1):e2250647.', 'journal-title': 'JAMA Netw Open'}, { 'key': '753_CR5', 'doi-asserted-by': 'publisher', 'first-page': '693', 'DOI': '10.1056/NEJMoa2021436', 'volume': '384', 'author': 'P Horby', 'year': '2021', 'unstructured': 'Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized ' 'patients with COVID-19. N Engl J Med. 2021;384:693–704.', 'journal-title': 'N Engl J Med'}, { 'issue': '2', 'key': '753_CR6', 'doi-asserted-by': 'publisher', 'first-page': '115', 'DOI': '10.37201/req/158.2021', 'volume': '35', 'author': 'A García-Lledó', 'year': '2022', 'unstructured': 'García-Lledó A, Gómez-Pavón J, González D, Castillo J, et al. ' 'Pharmacological treatment of COVID-19: an opinion paper. Rev Esp ' 'Quimioter. 2022;35(2):115–30.', 'journal-title': 'Rev Esp Quimioter'}, { 'issue': '6', 'key': '753_CR7', 'doi-asserted-by': 'publisher', 'first-page': 'e2231', 'DOI': '10.1002/rmv.2231', 'volume': '31', 'author': 'D Focosi', 'year': '2021', 'unstructured': 'Focosi D, Maggi F. Neutralising antibody escape of SARS-CoV-2 spike ' 'protein: risk assessment for antibody-based Covid-19 therapeutics and ' 'vaccines. Rev Med Virol. 2021;31(6):e2231.', 'journal-title': 'Rev Med Virol'}, { 'issue': '1', 'key': '753_CR8', 'doi-asserted-by': 'publisher', 'first-page': '250', 'DOI': '10.1038/s41467-020-20501-9', 'volume': '12', 'author': 'J Ge', 'year': '2021', 'unstructured': 'Ge J, Wang R, Ju B, et al. Antibody neutralization of SARS-CoV-2 through ' 'ACE2 receptor mimicry. Nat Commun. 2021;12(1):250.', 'journal-title': 'Nat Commun'}, { 'issue': '13', 'key': '753_CR9', 'doi-asserted-by': 'publisher', 'first-page': '4782', 'DOI': '10.3390/ijms21134782', 'volume': '21', 'author': 'A Allegra', 'year': '2020', 'unstructured': 'Allegra A, Di Gioacchino M, Tonacci A, Musolino C, Gangemi S. ' 'Immunopathology of SARS-CoV-2 infection: immune cells and mediators, ' 'prognostic factors, and immune-therapeutic implications. Int J Mol Sci. ' '2020;21(13):4782.', 'journal-title': 'Int J Mol Sci'}, { 'key': '753_CR10', 'doi-asserted-by': 'crossref', 'unstructured': 'Ling Z, Yi C, Sun X, Yang Z, Sun B. Broad strategies for neutralizing ' 'SARS-CoV-2 and other human coronaviruses with monoclonal antibodies. Sci ' 'China Life Sci. 2022:1–21.', 'DOI': '10.1007/s11427-022-2215-6'}, { 'key': '753_CR11', 'unstructured': 'Sisi S, Ruoke W, Qi Z. Zhang Linqi.Ambavirumab injection (BRII-196) and ' 'Romisisimab injection (BRII-198): China’s first independent intellectual ' 'property rights of neutralization and antibody combined therapy for ' 'COVID-19 [J]. Chin J Med. 2022,24(01):2–8.'}, { 'key': '753_CR12', 'unstructured': 'National Health Commission of China. New coronavirus pneumonia ' 'prevention and control program(9th ed). China Med,2022(04):481–7.'}, { 'issue': '8', 'key': '753_CR13', 'doi-asserted-by': 'publisher', 'first-page': 'e1008762', 'DOI': '10.1371/journal.ppat.1008762', 'volume': '16', 'author': 'A Mittal', 'year': '2020', 'unstructured': 'Mittal A, Manjunath K, Ranjan RK, et al. COVID-19 pandemic: insights ' 'into structure, function, and hACE2 receptor recognition by SARS-CoV-2. ' 'PLoS Pathog. 2020;16(8):e1008762.', 'journal-title': 'PLoS Pathog'}, { 'key': '753_CR14', 'doi-asserted-by': 'publisher', 'first-page': '115', 'DOI': '10.1038/s41586-020-2380-z', 'volume': '584', 'author': 'B Ju', 'year': '2020', 'unstructured': 'Ju B, Zhang Q, Ge J, et al. Human neutralizing antibodies elicited by ' 'SARS-CoV-2 infection. Nature. 2020;584:115–19.', 'journal-title': 'Nature'}, { 'issue': '10', 'key': '753_CR15', 'doi-asserted-by': 'publisher', 'first-page': '1706', 'DOI': '10.1016/j.clinthera.2021.08.009', 'volume': '43', 'author': 'JY Kim', 'year': '2021', 'unstructured': 'Kim JY, Jang YR, Hong JH, et al. Safety, virologic efficacy, and ' 'pharmacokinetics of CT-P59, a neutralizing monoclonal antibody against ' 'SARS-CoV-2 spike receptor-binding protein: two randomized, ' 'placebo-controlled, phase I studies in healthy individuals and patients ' 'with mild SARS-CoV-2 infection. Clin Ther. 2021;43(10):1706–27.', 'journal-title': 'Clin Ther'}, { 'issue': '12', 'key': '753_CR16', 'first-page': '1327', 'volume': '82', 'author': 'SM Hoy', 'year': '2022', 'unstructured': 'Hoy SM. Amubarvimab/Romlusevimab: first approval. Drugs. ' '2022;82(12):1327–31.', 'journal-title': 'First Approval Drugs'}, { 'issue': '5', 'key': '753_CR17', 'doi-asserted-by': 'publisher', 'first-page': '622', 'DOI': '10.1016/S1473-3099(21)00751-9', 'volume': '22', 'author': 'ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group', 'year': '2022', 'unstructured': 'ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group. ' 'Efficacy and safety of two neutralising monoclonal antibody therapies, ' 'sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with ' 'COVID-19 (TICO): a randomised controlled trial. Lancet Infect Dis. ' '2022;22(5):622–35.', 'journal-title': 'Lancet Infect Dis'}, { 'key': '753_CR18', 'doi-asserted-by': 'crossref', 'unstructured': 'Evering TH, Mark G, Chew KW, et al. LB2. Safety and efficacy of ' 'combination SARS-CoV-2 monoclonal neutralizing antibodies (mAb) BRII-196 ' 'and BRII-198 in non-hospitalized COVID-19 patients[J]. Open Forum Infect ' 'Di. 2021.', 'DOI': '10.1093/ofid/ofab466.1643'}, { 'issue': '1', 'key': '753_CR19', 'doi-asserted-by': 'publisher', 'first-page': '2315', 'DOI': '10.1080/22221751.2022.2117094', 'volume': '11', 'author': 'JM Seo', 'year': '2022', 'unstructured': 'Seo JM, Kang B, Song R, et al. Preclinical assessment and randomized ' 'phase I study of CT-P63, a broadly neutralizing antibody targeting ' 'severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Emerg ' 'Microbes Infect. 2022;11(1):2315–25.', 'journal-title': 'Emerg Microbes Infect'}, { 'key': '753_CR20', 'doi-asserted-by': 'publisher', 'first-page': 'eabf1906', 'DOI': '10.1126/scitranslmed.abf1906', 'volume': '13', 'author': 'BE Jones', 'year': '2021', 'unstructured': 'Jones BE, Brown-Augsburger PL, Corbett KS, et al. The neutralizing ' 'antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman ' 'primates. Sci Transl Med. 2021;13:eabf1906.', 'journal-title': 'Sci Transl Med'}, { 'key': '753_CR21', 'doi-asserted-by': 'publisher', 'first-page': '1110', 'DOI': '10.1126/science.abe2402', 'volume': '370', 'author': 'A Baum', 'year': '2020', 'unstructured': 'Baum A, Ajithdoss D, Copin R, et al. REGN-COV2 antibodies prevent and ' 'treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science. ' '2020;370:1110–5.', 'journal-title': 'Science'}, { 'issue': '21', 'key': '753_CR22', 'doi-asserted-by': 'publisher', 'first-page': '1941', 'DOI': '10.1056/NEJMoa2107934', 'volume': '385', 'author': 'A Gupta', 'year': '2021', 'unstructured': 'Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for Covid-19 ' 'with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. ' '2021;385(21):1941–50.', 'journal-title': 'N Engl J Med'}], 'container-title': 'BMC Pharmacology and Toxicology', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1186/s40360-024-00753-7.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1186/s40360-024-00753-7/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1186/s40360-024-00753-7.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 4, 19]], 'date-time': '2024-04-19T10:05:29Z', 'timestamp': 1713521129000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://bmcpharmacoltoxicol.biomedcentral.com/articles/10.1186/s40360-024-00753-7'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 4, 19]]}, 'references-count': 22, 'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2024, 12]]}}, 'alternative-id': ['753'], 'URL': 'http://dx.doi.org/10.1186/s40360-024-00753-7', 'relation': {}, 'ISSN': ['2050-6511'], 'subject': [], 'container-title-short': 'BMC Pharmacol Toxicol', 'published': {'date-parts': [[2024, 4, 19]]}, 'assertion': [ { 'value': '15 July 2023', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '10 April 2024', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '19 April 2024', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, {'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Declarations'}}, { 'value': 'The study was followed in accordance with the ethical standards of the ' 'responsible committee on human experimentation (institutional or regional) and ' 'with the Helsinki Declaration of 1975. The medical research record number is ' 'MR-50-20-002145 obtained from National Medical Research Registration and Filing ' 'System. Informed consent was obtained from all subjects or their legal ' 'guardians. The study was approved by the Hohhot First Hospital Research Ethics ' 'Commission on September 25th, 2022. Meanwhile it was also approved by Chongqing ' 'Public Health Treatment Center Research Ethics Commission.', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Ethics approval and consent to participate'}}, { 'value': 'NA.', 'order': 3, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Consent for publication'}}, { 'value': 'The authors declare no competing interests.', 'order': 4, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}], 'article-number': '29'}